---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027914"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:02:45.370473+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lipocine's PPD Phase 3 study hits 80% enrollment; DSMB review in Jan 2026

## Summary
- 66 of 80 planned participants randomized in Phase 3 trial of LPCN 1154 for postpartum depression.
- Second independent DSMB review planned for mid-January 2026; first review recommended continuation.
- Topline results expected Q2 2026; NDA submission under 505(b)(2) planned for 2026.
- Study conducted entirely outpatient; no medical monitoring required per FDA feedback.

## SEC filing metadata
- accession: 0001493152-25-027914
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225027914/0001493152-25-027914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225027914/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027914
- JSON: https://secwatch.observer/filing/0001493152-25-027914.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.